Gene Therapy Research Articles & Analysis
8 news found
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. ...
Ultimately, personalized medicine could be key in helping us tackle some of the world’s most pressing medical issues. Advances in gene therapy Gene therapy has made huge strides over the past decade due to advancements in technology and knowledge of human biology. This treatment is used to modify or replace an ...
Total capital raised of $330 million since the Company’s launch in 2020 Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5,000L bioreactors for research-to-commercial gene therapy manufacturing Forge Biologics, a gene therapy-focused contract ...
Riva has nearly 30 years’ experience in the Life Sciences industry and is currently CEO of Intima Bioscience which specializes in cell therapies for solid cancers. Prior to this role, he served as CEO of Ichnos Sciences and Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, ...
The roles of Chairman and Chief Executive Officer will be separated.Dr. Riva proposed as new independent Director and non-executive Chairman of the Board. With more than 30 years of experience in the industry, Dr. Riva will work with Transgene’s CEO Hedi Ben Brahim to realize the potential of the Company’s technology platforms and products to benefit cancer patients. ...
Brown was most recently at Voyager Therapeutics, where he was responsible for building the research organization and leading multiple gene-therapy discovery research programs. ...
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced positive interim safety, protein expression and biomarker data from the ongoing open-label Phase I/II FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) ...
” CMRI’s Executive Director, Professor Roger Reddel, said, “We are delighted that Dr Schlegel has chosen the Westmead Health Precinct as the most suitable environment for his CAR-T research program, which is complementary to the gene therapy and cancer research programs already at CMRI and with ...